Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM ET Company Participants Stuart Arbuckle - EVP, COO Conference Call Participants Paul Matteis - Stifel Paul Matteis Great, good morning. It's my pleasure to be moderating this chat with Stuart Arbuckle, COO of Vertex Pharmaceuticals. Good to see you again. We had a nice dinner last night. Stuart Arbuckle We did. Question-and-Answer Session Q - Paul Matteis Maybe to start, Stuart, I think we can have ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 9:00 AM ET Company Participants Reshma Kewalramani - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good morning, and thank you for joining Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit, one of the therapeutic analysts, and my privilege to welcome Dr. Reshma Kewalramani, President and CEO of Vertex. T ...

Regulators are reviewing what could become a multi-billion-dollar drug. Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle common health problems. Vertex Pharmaceuticals (VRTX -2.34%) has stood out over the past several years as a top biotech player, thanks to its work in the area of cystic fibrosis (CF). The company's portfolio of treatments is changing the lives of patients and bringing in blockbuster revenue -- in the most recent q ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average, which suggests a short-term bullish trend.The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages ...

From a technical perspective, Vertex Pharmaceuticals (VRTX) is looking like an interesting pick, as it just reached a key level of support. VRTX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average, which is one of three major moving averages, is widely used by traders and analysts to establish support and resistance levels for a range of securities. Because it's the first sign of an up or down trend, the 50-day is considered to be more i ...

Vertex Pharmaceuticals (VRTX) reported $2.77 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.6%. EPS of $4.38 for the same period compares to $4.08 a year ago.The reported revenue represents a surprise of +3.62% over the Zacks Consensus Estimate of $2.67 billion. With the consensus EPS estimate being $4.13, the EPS surprise was +6.05%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare ...

Table of Contents | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------- ...

Vertex Pharmaceuticals Incorporated (VRTX) reported adjusted earnings of $4.38 per share for the third quarter of 2024, surpassing the Zacks Consensus Estimate of $4.13. In the year-ago quarter, the company had recorded adjusted earnings of $4.08 per share. Earnings grew year over year owing to increased product revenues.The company reported total revenues of $2.77 billion for the third quarter, comprising cystic fibrosis (CF) product revenues. The figure beat the Zacks Consensus Estimate of $2.67 billion. ...

THIRD QUARTER 2024 FINANCIAL RESULTS ©2024 Vertex Pharmaceuticals Incorporated VERTEX NOVEMBER 4, 2024 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2024 Vertex Pharmaceuticals Incorporated 2 SAFE HARBOR ...

Financial Data and Key Metrics Changes - Q3 2024 revenue reached $2.77 billion, reflecting a 12% year-over-year growth, with 10% growth in the U.S. and 14% growth outside the U.S [56] - Year-to-date revenue totaled $8.1 billion, representing a 10% increase compared to the same period in 2023 [56] - The company raised its full-year product revenue guidance to a range of $10.8 billion to $10.9 billion, indicating a strong outlook for Q4 [62] Business Line Data and Key Metrics Changes - In cystic fibrosis (CF), revenue was $2.77 billion, marking a 12% increase compared to Q3 2023 [8] - The early launch of CASGEVY has begun, with the first patient receiving treatment in Q3, contributing to initial revenue recognition [9] - The company is preparing for potential launches of vanzacaftor triple in CF and suzetrigine in acute pain in early 2025 [10] Market Data and Key Metrics Changes - The company has activated 45 authorized treatment centers for CASGEVY, up from over 35 in Q2 [37] - Approximately 40 patients have undergone cell collection for CASGEVY, indicating growing demand [37] - The payer landscape remains favorable, with no significant access barriers reported in the U.S. for CASGEVY [38] Company Strategy and Development Direction - Vertex aims to diversify revenue streams with the launch of CASGEVY and upcoming products, targeting five new product launches over five years [10] - The company is investing in additional manufacturing capacity for CASGEVY to meet anticipated demand [40] - The strategic focus for suzetrigine includes securing broad access and ensuring a seamless experience for patients and physicians [49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained revenue growth in CF and the potential for new product launches to drive future growth [34] - The company is optimistic about the upcoming regulatory approvals and the progress of its clinical pipeline [64] - Management highlighted the significant unmet need in pain management, reinforcing the potential market for suzetrigine [43] Other Important Information - The company reported a non-GAAP operating income of $1.31 billion for Q3 2024, compared to $1.17 billion in Q3 2023 [60] - Vertex ended the quarter with $11.2 billion in cash and investments, with significant share repurchases ongoing [61] Q&A Session Summary Question: Discussion on at-home delivery for povetacicept - Management confirmed plans for povetacicept to be delivered at-home monthly for commercial approval, with regulatory interactions already in place [67] Question: Efficacy expectations for suzetrigine in LSR - Management indicated they are looking for statistically significant results in NPRS scores and are confident in the trial design and patient selection [75] Question: Pricing considerations for suzetrigine - Pricing decisions will consider clinical benefits and unmet needs at both individual and societal levels, with final decisions made closer to approval [79] Question: Comparison of VX-548 and Lyrica - Management clarified that VX-548 and Lyrica have different mechanisms of action, with VX-548 specifically targeting NaV1.8 channels [82] Question: Insights from CASGEVY commercial process - Management noted the importance of patient and physician discussions regarding the treatment journey and the enthusiasm from payers and policymakers for CASGEVY [102]